Screening for hepatocellular carcinoma

Jarosław Koza, Krzysztof Orłowski, Adam Jurgoński, Agnieszka Meder, Małgorzata Pujanek, Monika Ameryk, Renata Kwiatkowska, Maciej Świątkowski

Abstract


Introduction and purpose of the work. Hepatocellular carcinoma (HCC) is one of the most common malignant tumours all over the world. It is considered to be the sixth malignant tumour in terms of incidence. It is also characterized by high mortality rate, which, depending on the geographic region, gives the second or third place on the list of cancer related death. There are many known risk factors for the development of hepatocellular carcinoma, the most important of which is liver cirrhosis. Thus the cirrhotic patients are generally accepted for screening. Actually it is recommended to perform abdominal ultrasound every 6 months in this group. Other forms of screening are also tested.

Description of the current knowledge and conclusions.

Literature review provides indisputable evidences for the need of screening for liver cancer. Doubts remain only about the appropriateness of widening the screening group and possibly extending the scope of diagnostic tools.

The authors, by analyzing the available knowledge for hepatocellular carcinoma screening, consider the qualification of actually recommended screening tests to be insufficient in countries with high incidence. Relatively high incidence of HCC, even greater mortality in the context of all cancers, safety, low cost and universal access to ultrasound, should, in the opinion of the authors, be enough for the consideration to widen the screening guidelines in countries with high incidence of HCC. In countries with low incidence, e.g. in Poland, the screening in healthy population do not belong to the priority.


Full Text:

PDF

References


Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al.. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017; 7; 23 (29): 5282-5294.

Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic

management of hepatocellular carcinoma. World J Gastroenterol. 2015; 14; 21 (42): 12003-12021.

Limaiem F, Bouhamed M, Sahraoui G, Mzabi S. Hepatocellular carcinoma: a

clinicopathological study of 64 cases. Pan Afr Med J. 2017; 16; 27:41.

Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 8; 371 (9615): 838-851.

Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24 (3): 1073274817729245. doi: 10.1177/1073274817729245.

Chen S, Duan W, You H, Jia J. A brief review on prognostic models of primary

biliary cholangitis. Hepatol Int. 2017; 14. doi: 10.1007/s12072-017-9819-9.

Singh S., Talwalkar J.A. Primary sclerosing cholangitis: Diagnosis, prognosis, and management. Clin. Gastroenterol. Hepatol. 2013; 11:898–907. doi: 10.1016/j.cgh.2013.02.016.

Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J

Gastroenterol. 2014; 21; 20 (23):7312-7324.

Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases

affecting the liver and liver diseases affecting the heart. Am Heart J. 2000; 140 (1): 111-120.

Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for

hepatocellular carcinoma? J Hepatol. 2012; 57 (2): 453-454.

Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Risk

factors analysis for hepatocellular carcinoma in patients with and without

cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from

India. J Gastroenterol Hepatol. 2007; 22 (7): 1104-1111.

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in

cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl.

: S35-50.

Fateen W, Ryder SD. Screening for hepatocellular carcinoma: patient selection

and perspectives. J Hepatocell Carcinoma. 2017; 17; 4: 71-79.

Kuo MJ, Chen HH, Chen CL, Fann JC, Chen SL, Chiu SY, et al. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol. 2016; 28; 22 (12):m 3460-3670.

Ungtrakul T, Mahidol C, Chun-On P, Laohapand C, Siripongsakun S,

Worakitsitisatorn A, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016; 14; 22 (34): 7806-12.

Singal A, Conjeevaram H, Volk N, Fu S, Fontana R, Askari F, et al. Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012; OF1-7. DOI: 10.1158/1055-9965.EPI-11-1005.

Blehar DJ, Barton B, Gaspari RJ. Learning curves in emergency ultrasound

education. Acad Emerg Med. 2015; 22 (5): 574-582.

Andoulo F A, Noah DN, Djapa R, Kowo M, Talla P, Medjo EH et al. Epidemiology of hepatitis C: related hepatocellular carcinoma in Cameroon. Pan Afr Med J. 2014; 15; 19:379. doi: 10.11604/pamj.2014.19.379.4143.

Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic

management of hepatocellular carcinoma. World J Gastroenterol. 2015;

; 21 (42): 12003-21. doi: 10.3748/wjg.v21.i42.12003.

El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and

how? Therap Adv Gastroenterol. 2011; 4 (1): 5-10.

Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, et al. Contrast-enhanced US with Perfluorobutane (Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer. 2017; 18; 17 (1): 279. doi: 10.1186/s12885-017-3267-8.

Kudo M. Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in

Hepatocellular Carcinoma. Liver Cancer. 2016; 5 (1): 1-7.

Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer

Mortality, Incidence, and Survival in the United States, 1950-2014: Over Six

Decades of Changing Patterns and Widening Inequalities. J Environ Public Health.

; 2017: 2819372. doi: 10.1155/2017/2819372.

Singh GK, Siahpush M, Altekruse SF. Time trends in liver cancer mortality,

incidence, and risk factors by unemployment level and race/ethnicity, United

States, 1969-2011. J Community Health. 2013; 38 (5): 926-940.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017; 1; 109 (9). doi: 10.1093/jnci/djx030.

Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009; 50 (1): 80-88.

Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010, 1; 28 (10): 1660-1665.

Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, et al. ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology. 2016; 64 (4): 1136-1147.

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with

direct-acting antivirals. J Hepatol. 2016; 65 (4): 727-733.

Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R,

Stättermayer AF, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016; 65 (4): 856-858.

Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy

for hepatitis C associated cirrhosis. J Hepatol. 2016; 65 (5): 1070-1071.

Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, et al. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016; 43 (5): 621-30.

Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of

hepatocellular carcinoma surveillance among American patients: a systematic

review. J Gen Intern Med. 2012; 27 (7): 861-867.

Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016; 65 (8): 1151-1160.

Krgyrou C, Moris D, Vernadakis S. Hepatocellular carcinoma development in

non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. J BUON. 2017; 22 (1): 6-20.

Charrez B, Qiao L, Hebbard L. Hepatocellular carcinoma and non-alcoholic

steatohepatitis: The state of play. World J Gastroenterol. 2016; 28; 22(8): 2494-2502.

Krzakowski M, Zieniewicz K, Habior A, Horban A, Olszewski W, Cianciara J, et al. Rak wątrobowokomórkowy — rozpoznanie i leczenie. Onkol. Prak. Klin. 2009; 5, 4: 125–140.

Pan J, Xin L, Ma YF, Hu LH, Li ZS. Colonoscopy Reduces Colorectal Cancer

Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis.

Am J Gastroenterol. 2016; 111 (3): 355-465.

Świątkowski M, Meder A, Sobczyński L, Koza J, Szamocka M, Brudny J, Korenkiewicz J. Adenomas detected during screening colonoscopies in the years 2000-2009. Przegl. Gastroenterol. 2012 : Vol. 7, nr 5, s. 299-305.

Świątkowski M, Meder A, Sobczyński L, Koza J, Szamocka M, Brudny J. The screening program for the early colorectal cancer detection performed at the Gastroenterology Department of Nicolaus Copernicus University in Toruń Collegium Medicum in Bydgoszcz in 2000-2009. Gastroenterol. Pol. 2010: 17, 6: 410-415.




DOI: http://dx.doi.org/10.5281/zenodo.1045341

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

Journal Language(s): English 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2  www.ukw.edu.pl Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy http://ojs.ukw.edu.pl/index.php/johs  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase Index.com.

Website: www.infobaseindex.com

Universal Impact Factor 1.78 for year 2012. (http://www.uifactor.org/AppliedJournals.aspx)

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)